Moderna (MRNA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.84 (-6.22%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Moderna (MRNA)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $45.65
  • Market Cap

    $17.57 Billion
  • Total Outstanding Shares

    384.82 Million Shares
  • Total Employees

    5,600
  • Dividend

    No dividend
  • IPO Date

    December 7, 2018
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.modernatx.com

Historical Stock Splits

If you bought 1 share of MRNA before July 22, 2010, you'd have 0.00 shares today.
Execution DateSplit Amount
August 3, 20171-for-10 (Reverse Split)
December 23, 20111-for-10 (Reverse Split)
July 22, 20101-for-4 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$1.95 Billion
Net Cash Flow$-1.31 Billion
Net Cash Flow From Operating Activities$-3.21 Billion
Net Cash Flow, Continuing$-1.31 Billion
Net Cash Flow From Financing Activities$-50.00 Million
Net Cash Flow From Operating Activities, Continuing$-3.21 Billion
Net Cash Flow From Financing Activities, Continuing$-50.00 Million
Net Cash Flow From Investing Activities$1.95 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Equity Method Investments$-62.00 Million
Income/Loss From Continuing Operations After Tax$-2.22 Billion
Net Income/Loss Available To Common Stockholders, Basic$-2.22 Billion
Research and Development$4.83 Billion
Cost Of Revenue$1.65 Billion
Net Income/Loss Attributable To Parent$-2.22 Billion
Income/Loss From Continuing Operations Before Tax$-2.35 Billion
Operating Income/Loss$-2.69 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss Before Equity Method Investments$-2.29 Billion
Diluted Average Shares$782.00 Million
Other Operating Expenses$1.29 Billion
Basic Average Shares$768.00 Million
Costs And Expenses$7.77 Billion
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$7.43 Billion
Basic Earnings Per Share$-5.82
Diluted Earnings Per Share$-5.82
Revenues$5.08 Billion
Gross Profit$3.43 Billion
Operating Expenses$6.12 Billion
Net Income/Loss$-2.22 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income Tax Expense/Benefit$-129.00 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$15.80 Billion
Noncurrent Liabilities$1.68 Billion
Other Current Liabilities$1.58 Billion
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$3.88 Billion
Noncurrent Assets$6.14 Billion
Equity$11.93 Billion
Wages$244.00 Million
Inventory$412.00 Million
Current Liabilities$2.20 Billion
Current Assets$9.67 Billion
Accounts Payable$373.00 Million
Other Current Assets$9.25 Billion
Assets$15.80 Billion
Equity Attributable To Parent$11.93 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Moderna (MRNA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.